Hemodialysis Concentrate Solution
Mid Atlantic Nephrology Center
FDA Clearance Information
The hemodialysis concentrate solution by Mid Atlantic Nephrology Center was cleared via the FDA 510k pathway on April 8, 1980. It is classified as a Class 2 device.
What It Is
FDA-Cleared Indications
- For preparation of dialysate used during hemodialysis.
- For use in patients receiving hemodialysis when a dialysate concentrate is required.
Clinical Applications
- Preparing dialysate for intermittent hemodialysis.
- Supporting removal of metabolic waste products during hemodialysis.
- Supporting control of electrolyte and acid-base balance during dialysis treatment.
- Use in dialysis centers or other clinical settings equipped to dilute and deliver dialysate.
Evidence Summary
Reported Outcomes
Safety Profile
Evidence Limitations
Practical Considerations
- The concentrate must be diluted with the specified quality of treated water and used with a compatible dialysis machine or proportioning system.
- The formulation, concentration, mixing ratio, and electrolyte composition must match the dialysis prescription and equipment instructions.
- It is not administered directly into a vein; improperly diluted concentrate can cause serious electrolyte or acid-base disturbances.
- Storage, handling, labeling, expiration, and contamination-control requirements should follow the product labeling and dialysis-facility procedures.
- MRI compatibility is generally not applicable to the solution itself, but the dialysis machine and associated equipment require separate evaluation before use in an MRI environment.
Frequently Asked Questions
What are the clinical indications for hemodialysis concentrate solution?
The clinical indications include use in hemodialysis to maintain electrolyte balance and remove waste products from the blood.
What outcomes have been reported in clinical studies?
Studies report effective electrolyte balance maintenance and improved eco-sustainability in dialysis centers.
What complications have been reported?
Safety data indicate increased plasma viscosity in hemodiafiltration due to high ultrafiltration volumes.